Physician profile
Thomas J Dobleman
NPI 1447343405
$3,201.12
in general payments reported to CMS, 2019-2025
15 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $594 · 2021: $471 · 2022: $554 · 2023: $327 · 2024: $450 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,422.05 | 2019-2025 | |
| Optinose US, INC. | $391.76 | 2019-2023 | |
| Stryker Corporation | $358.77 | 2019-2022 | |
| Intersect Ent, INC. | $276.05 | 2019-2022 | |
| Acclarent, INC | $262.82 | 2019-2022 | |
| Kaleo, INC. | $229.84 | 2021-2023 | Auvi-Q |
| Biohaven Pharmaceuticals, INC. | $79.19 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $44.25 | 2021-2025 | Dupixent |
| Mimedx Group, INC. | $32.83 | 2025 | |
| Pacira Therapeutics, INC. | $19.46 | 2019 | |
| Alk-Abello, INC | $18.13 | 2021 | |
| Glaxosmithkline, LLC. | $17.26 | 2023 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $17.19 | 2025 | Neffy |
| Amgen INC. | $15.91 | 2019 | |
| Merck Sharp & Dohme LLC | $15.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dobleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.